Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

BMC Cancer. 2008;8(1):230 DOI 10.1186/1471-2407-8-230

 

Journal Homepage

Journal Title: BMC Cancer

ISSN: 1471-2407 (Online)

Publisher: BMC

LCC Subject Category: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS

Gleave Martin E
Rajput Ashish B
Fazli Ladan
Hurtado-Coll Antonio
Kwon Erika M
Miller Melinda A
Johnson Karynn
Agalliu Ilir
FitzGerald Liesel M
Cox Michael E
Ostrander Elaine A
Stanford Janet L
Huntsman David G

EDITORIAL INFORMATION

Open peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 19 weeks

 

Abstract | Full Text

<p>Abstract</p> <p>Background</p> <p>The presence of the TMPRSS2-ERG fusion gene in prostate tumors has recently been associated with an aggressive phenotype, as well as recurrence and death from prostate cancer. These associations suggest the hypothesis that the gene fusion may be used as a prognostic indicator for prostate cancer.</p> <p>Methods</p> <p>In this study, fluorescent <it>in situ </it>hybridization (FISH) assays were used to assess TMPRSS2-ERG fusion status in a group of 214 prostate cancer cases from two population-based studies. The FISH assays were designed to detect both fusion type (deletion vs. translocation) and the number of fusion copies (single vs. multiple). Genotyping of four <it>ERG </it>and one <it>TMPRSS2 </it>SNPs using germline DNA was also performed in a sample of the cases (n = 127).</p> <p>Results</p> <p>Of the 214 tumors scored for the TMPRSS2-ERG fusion, 64.5% were negative and 35.5% were positive for the fusion. Cases with the TMPRSS2-ERG fusion did not exhibit reduced prostate cancer survival (HR = 0.92, 95% CI = 0.22–3.93), nor was there a significant difference in cause-specific survival when stratifying by translocation or deletion (HR = 0.84, 95% CI = 0.23–3.12) or by the number of retained fusion copies (HR = 1.22, 95% CI = 0.45–3.34). However, evidence for reduced prostate cancer-specific survival was apparent in those cases whose tumor had multiple copies of the fusion. The variant T allele of the <it>TMPRSS2 </it>SNP, rs12329760, was positively associated with TMPRSS2-ERG fusion by translocation (p = 0.05) and with multiple copies of the gene fusion (p = 0.03).</p> <p>Conclusion</p> <p>If replicated, the results presented here may provide insight into the mechanism by which the TMPRSS2-ERG gene fusion arises and also contribute to diagnostic evaluations for determining the subset of men who will go on to develop metastatic prostate cancer.</p>